Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites
- PMID: 11073270
- DOI: 10.1093/ndt/15.suppl_5.18
Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites
Abstract
Chronic renal failure is characterized by diminished synthesis of, and resistance to, the active vitamin D metabolite 1,25-dihydroxy-vitamin D3 (1,25(OH)2D3, calcitriol). Calcitriol results from the biotransformation of the precursor 25-hydroxy-vitamin D3 (25(OH)D3) to 1,25(OH)2D3. 25(OH)D3 is synthesized in the liver, and 1alpha-hydroxylase, the rate-limiting enzyme for its biotransformation into the most active metabolite, 1,25(OH)2D3, is located in the kidney. The regulation of 1alpha-hydroxylase in renal failure is not well known. Recent work indicates that, in contrast to previous opinion, 1alpha-hydroxylase is predominantly expressed not in the proximal tubule but in the distal tubule [1]. In vivo, the main stimulatory signal is presumably parathyroid hormone (PTH) and the main inhibitory signal hyperphosphataemia. Both signals are altered in renal failure. There is also evidence that the renal 1alpha-hydroxylase becomes substrate-dependent in patients with renal failure. This means that a higher concentration of the precursor 25(OH)2D3 will result in a higher rate of transformation into the active metabolite 1,25(OH)2D3 in renal patients. Calcitriol is not exclusively synthesized in the kidney, but may also be synthesized in extra-renal tissues, e.g. activated monocytes/macrophages [2], particularly in granuloma [3] as shown by anephric uraemic patients who develop hypercalcaemia and elevated calcitriol concentrations when sarcoidosis [4] or tuberculosis [5] supervenes. On the other hand, calcitriol is less effective in uraemia. This may be to some extent due to diminished expression of vitamin D receptors [6], particularly in parathyroid glands when they undergo nodular transformation [7], but there may also be resistance to calcitriol at the post-receptor level [8]. In a series of elegant experiments [9,10], calcitriol resistance has been related to disturbed genomic effects of active vitamin D because the interaction of the vitamin D receptor ligand complex with vitamin D-responsive elements (VDREs) upstream of vitamin D-regulated genes was disturbed by the action of low molecular weight substances in uraemia, which have not been completely characterized. The role of genetically determined polymorphisms of the vitamin D receptor in the genesis of disturbed calcium metabolism of renal failure is currently unclear.
Similar articles
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.J Clin Invest. 1984 Dec;74(6):2136-43. doi: 10.1172/JCI111639. J Clin Invest. 1984. PMID: 6549016 Free PMC article.
-
Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals.Endocrinology. 1999 May;140(5):2224-31. doi: 10.1210/endo.140.5.6691. Endocrinology. 1999. PMID: 10218975
-
[Vitamin D metabolism in kidney insufficiency: disorders of an endocrine regulatory zone].Klin Wochenschr. 1979 Oct 1;57(19):1053-9. doi: 10.1007/BF01479991. Klin Wochenschr. 1979. PMID: 392179 Review. German.
-
1α,24(S)(OH)2D2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism.J Endocrinol Invest. 2008 Aug;31(8):711-7. doi: 10.1007/BF03346420. J Endocrinol Invest. 2008. PMID: 18852532
Cited by
-
Immune dysfunction in uremia—an update.Toxins (Basel). 2012 Oct 24;4(11):962-90. doi: 10.3390/toxins4110962. Toxins (Basel). 2012. PMID: 23202302 Free PMC article. Review.
-
Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.Clin Drug Investig. 2006;26(11):629-38. doi: 10.2165/00044011-200626110-00002. Clin Drug Investig. 2006. PMID: 17163297 Review.
-
Vitamin D and Anaesthesia.Turk J Anaesthesiol Reanim. 2015 Aug;43(4):269-73. doi: 10.5152/TJAR.2015.28482. Epub 2015 Mar 3. Turk J Anaesthesiol Reanim. 2015. PMID: 27366509 Free PMC article. Review.
-
Alterations in serum phosphate levels predict the long-term response to intravenous calcitriol therapy in dialysis patients with secondary hyperparathyroidism.J Bone Miner Metab. 2008;26(2):185-90. doi: 10.1007/s00774-007-0809-1. Epub 2008 Feb 27. J Bone Miner Metab. 2008. PMID: 18301976 Clinical Trial.
-
Immune Dysfunction in Uremia 2020.Toxins (Basel). 2020 Jul 5;12(7):439. doi: 10.3390/toxins12070439. Toxins (Basel). 2020. PMID: 32635646 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources